drugset / Trial / NCT02256826

Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects

NCT02256826

Phase 1 Completed 34 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine the pharmacokinetic effect of BILR 355 BS on Kaletra® and of Kaletra® on BILR 355 BS

Timeline

Start
2005-04
Primary completion
2005-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BILR 355 BS Unknown
Subject Lopinavir Other / unclassified
Background Ritonavir Other / unclassified

Indications

No indication recorded.